ELIGARD 22.5mg Injection contains the active substance Leuprolide Acetate. It belongs to a group of medicines known as Gonadotropin-Releasing Hormone (GnRH) Agonists. It is primarily used for the treatment of advanced prostate cancer by reducing testosterone levels, which helps slow the growth of hormone-dependent cancer cells.
ELIGARD works through Androgen Deprivation Therapy (ADT). Continuous treatment suppresses testosterone production, helping control disease progression and improve symptoms associated with advanced prostate cancer.
The 22.5mg formulation is a long-acting depot injection that is administered once every 3 months under the supervision of a qualified healthcare professional.
Uses of ELIGARD 22.5mg Injection
- Advanced Prostate Cancer
- Hormone-Dependent Prostate Cancer
- Long-Term Testosterone Suppression
- Palliative Management of Prostate Cancer Symptoms
- Androgen Deprivation Therapy (ADT)
Therapeutic Effects of ELIGARD 22.5mg Injection
ELIGARD works by initially stimulating and then suppressing the release of hormones responsible for testosterone production. Over time, testosterone levels fall to very low levels, reducing stimulation of prostate cancer cells and slowing disease progression.
Interaction of ELIGARD 22.5mg Injection with Other Drugs
It is important to inform your healthcare professional about all medicines you are taking.
Notable interactions include:
- Anti-androgen medicines
- Diabetes medications
- Heart rhythm medicines
- Blood pressure medications
- Chemotherapy agents
- Other hormonal therapies for prostate cancer
More Information about ELIGARD 22.5mg Injection
- Keep out of reach of children.
- Store according to package instructions.
- Protect from excessive heat and direct sunlight.
- Administer only by trained healthcare professionals.
- Do not use expired medication.
How to Consume ELIGARD 22.5mg Injection
ELIGARD 22.5mg is administered as a subcutaneous (under the skin) injection by a healthcare professional.
The 22.5mg depot formulation is designed to provide continuous drug release for 3 months, requiring only one injection every three months.
Safety Advice for ELIGARD 22.5mg Injection
Breast Feeding
Not Applicable
This medicine is generally used in male patients.
Alcohol
Caution
Alcohol may worsen dizziness, fatigue, and weakness.
Liver
Caution
Use under medical supervision in patients with liver disorders.
Kidneys
Caution
Patients with kidney impairment should be monitored during treatment.
Driving
Caution
ELIGARD may cause dizziness, fatigue, or weakness. Avoid driving if affected.
Pregnancy
Contraindicated
Not intended for use during pregnancy.
Side Effects of ELIGARD 22.5mg Injection
Side effects are unwanted symptoms caused by medicines. Although not everyone experiences them, some patients may develop side effects.
Common Side Effects of ELIGARD 22.5mg Injection
- Hot flashes
- Fatigue
- Injection site reactions
- Joint pain
- Weight gain
- Dizziness
- Headache
- Reduced libido
Serious Side Effects of ELIGARD 22.5mg Injection
- High blood sugar levels
- Diabetes
- Heart-related complications
- Severe allergic reactions
- Seizures
- Respiratory complications
- Bone density loss (osteoporosis)
Word of Advice
Patients receiving ELIGARD should undergo regular monitoring of PSA levels, testosterone levels, blood sugar, cardiovascular health, and bone density. During the first few weeks of treatment, symptoms may temporarily worsen due to an initial rise in testosterone (tumor flare) before hormone suppression occurs. Contact your doctor immediately if you experience severe bone pain, breathing difficulties, chest pain, or neurological symptoms.
FAQs about ELIGARD 22.5mg Injection
Q1. What is ELIGARD 22.5mg Injection used for?
It is used for the treatment and long-term management of advanced prostate cancer.
Q2. How does ELIGARD work?
It reduces testosterone production, helping slow the growth of hormone-sensitive prostate cancer cells.
Q3. How often is ELIGARD 22.5mg administered?
The 22.5mg depot injection is administered once every 3 months.
Q4. Can ELIGARD cure prostate cancer?
No. It helps control and manage advanced prostate cancer but is not considered a cure.
Q5. What is a tumor flare?
A temporary increase in symptoms may occur during the first few weeks of treatment due to an initial rise in testosterone levels before suppression begins.
Fact Box of ELIGARD 22.5mg Injection
Molecule Name: Leuprolide Acetate 22.5mg
Therapeutic Class: Antineoplastic / Hormonal Therapy
Pharmacological Class: Gonadotropin-Releasing Hormone (GnRH) Agonist
Indications: Advanced Prostate Cancer, Hormone-Dependent Prostate Cancer, Androgen Deprivation Therapy (ADT), Long-Term Testosterone Suppression.
